The emergence of data from clinical trials of biologics, the approval of new biologics, and
our improved understanding of psoriasis pathogenesis have increased the therapeutic …

Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is
associated with multiple comorbidities with a considerable reduction in quality of life of …

Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of
children, with onset most common during adolescence. This guideline addresses important …

Background Secukinumab has demonstrated sustained long‐term efficacy with a favourable
safety profile in various psoriatic disease manifestations in adults. Objectives Here, the …

Background Psoriasis affects 0.13%-2.1% of children and adolescents. Despite a high
unmet need, the current treatment options approved for pediatric psoriasis are limited …

The precipitating factors for stigma vary widely depending on age, sex, and culture. In order
to effectively reduce the impact of pediatric skin diseases on psychosocial health, physicians …

Background Biologics represent a promising treatment for children with moderate‐to‐severe
psoriasis. Randomized control trials (RCTs) have been published evaluating different …

Importance Few studies have compared the use of methotrexate and biologics, the most
commonly used systemic medications for treatment of moderate to severe psoriasis in …

Background Psoriasis is a chronic, immune-mediated inflammatory disease with prominent
cutaneous features, although the limited number of medications approved for pediatric …

Celiac disease (CD) is an immune-mediated enteropathy caused by gluten ingestion,
affecting approximately 1% of the worldwide population. Extraintestinal symptoms may be …